Repligen, ImClone In Patent Dispute Over Erbitux Cell Lines
Repligen is seeking damages from ImClone for allegedly using a cell line covered by a Repligen patent to produce the oncologic. The patent expired in May, but Repligen seeks to hold ImClone liable for product that was manufactured before the patent’s expiration.